Josephine Mak Waikato Cardiothoracic Unit Journal Club

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
RITA-3 ESC 4 th September 2005 The impact of underlying risk and gender on the benefit of early intervention in non-ST elevation acute coronary syndrome.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Invasive Versus Conservative Strategy in Patients Aged 80 years or Older with NSTEMI or Unstable Angina(After Eighty study) Nicolai Tegn, Michael Abdelnoor,
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Angela Aziz Donnelly April 5, 2016
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Cardiac causes of cardiac arrest
Total Occlusion Study of Canada (TOSCA-2) Trial
Nephrology Journal Club The SPRINT Trial Parker Gregg
A Clinical profile of patients enrolled in the Pakistan ACS registry
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The American College of Cardiology Presented by Dr. Adnan Kastrati
Should we care about post-procedural troponin in elective coronary stenting ?   Michel Zeitouni, Johanne Silvain*, Mathieu Kerneis, Olivier Barthelemy,
The British Heart Foundation older patients with non-ST SEgmeNt elevatIOn myocaRdial infarction Randomized Interventional TreAtment Trial The BHF SENIOR-RITA.
PRESENTER NAME Waikato Cardiothoracic Unit Journal Club
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
The European Society of Cardiology Presented by Dr. Saman Rasoul
Ischaemic Heart Disease Acute Coronary Syndrome
PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.
AIM HIGH Niacin plus Statin to prevent vascular events
RAAS Blockade: Focus on ACEI
Jeff Macemon Waikato Cardiothoracic Unit
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Dabigatran in myocardial injury after noncardiac surgery
Giuseppe Biondi Zoccai
ClinicalTrials.gov Identifier NCT
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
European Heart Association Journal 2007 April
NOACS: Emerging data in ACS/IHD
European Society of Cardiology 2003
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Press Conference Title
Monthly Journal article review: Vimmi Kang PGY 2
Invasive versus conservative treatment in unstable coronary syndromes
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
The European Society of Cardiology Presented by RJ De Winter
Impact of Platelet Reactivity Following Clopidogrel Administration
American College of Cardiology Presented by Dr. Michel R. Le May
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Global Registry of Acute Coronary Events: GRACE
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Implications of Preoperative Thienopyridine Use
What oral antiplatelet therapy would you choose?
ARISE Trial Aggressive Reduction of Inflammation Stops Events
These slides highlight a report from a Hotline Session and a Satellite symposium held at the European Society of Cardiology Congress, 2003 in Vienna Austria,
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Josephine Mak Waikato Cardiothoracic Unit Journal Club After 80 Josephine Mak Waikato Cardiothoracic Unit Journal Club

INTRODUCTION

Background NSTEMI and unstable angina result in many hospital presentations and admissions Mortality from ACS has decreased over the past 20 years with the development of modern treatment strategies such as revascularisation and better medical treatment Multiple guidelines now exist for management of ACS now – eg. European Society of Cardiology, American Heart Association, American College of Cardiology in younger age groups Based off large RCTS – however patients over 80 are under-represented thus proper subanalysis uncertain

Evidence “Non ST-elevation MI in the elderly” and “Acute coronary syndrome in the elderly” Meta-analysis of FRISC II, ICTUS, RITA-3 trials suggest that patients > 75yo benefit from invasive strategy but underpowered for >80yo Italian Elderly Acute Coronary syndrome study = “systematic early invasive approach does not confer significant clinical advantage compared to an initially conservative approach with angiography and revascularization only in the case of recurrent ischemia” – however also underpowered

AIMs To investigate if patients aged 80 years or older would benefit from an early invasive strategy versus a conservative strategy Invasive = early coronary angiography with immediate assessment for ad- hoc percutaneous coronary intervention, coronary artery bypass graft, or optimum medical treatment Conservative = optimum medical treatment

Outcomes Primary Outcomes composite primary endpoint of myocardial infarction, need for urgent revascularisation, stroke, and death Secondary Outcomes Death from any cause

Methodology

Methods 10 Dec 2010 – 21 Feb 2014 16 hospitals in South-East health Region of Norway without percutaneous coronary intervention facilities sealed opaque envelopes Non-blinded Intention to treat analysis Median follow-up of 1.53 years In 2001 Study, >75yo with NSTEMI had an incidence of composite endpoints (death and myocardial infarction) of 21% at 6 months, percutaneous coronary intervention had a lower incidence of composite endpoints (10·8%) = 10% in absolute risk and 50% in relative risk Assuming a type I error of 5% and power of 80% = 206 patients per group 412 patients would be needed for the study in total -> 450 at least entrolled

Methods – inclusion Criteria Consecutive Patients aged 80 or older NSTEMI or unstable angina, with/without ST-segment depression in ECG, with normal or raised blood concentration of troponin T or I No chest pain or other ischaemic symptoms/signs after medical treatment and mobilization Assessed by local cardiologist

Methods – Exclusion Criteria clinically unstable with continuing chest pain or other ischaemic symptoms or signs cardiogenic shock continuing bleeding problems short life expectancy (<12 months) because of serious comorbidity (such as chronic obstructive pulmonary disease, disseminated malignant disease, or other reasons). Substantial mental disorder

Methods – Study Protocol Randomised open label controlled multicentre trial Permuted block randomisation by centre of biostatistics and epidemiology Patients assessed for participation within 2 days after hospital admission Invasive – transferred to oslo university then transferred back within: 6-18 hours if underwent PCI 4-6 hours if underwent angiography alone Each angiogram reviewed by at least 2 interventional cardiologists before revascularisation method decided upon

Methods – Study Protocol Conservative – medical treatment in community hospital medically treated according to “existing guidelines” If reinfarcton, refractory angina pectoris despite optimum medical treatment, malignant ventricular arrhythmias, or increasing symptoms of heart failure, considered for urgent invasive coronary angiogram DAPT – mostly Aspirin and clopidogrel (although some ticagrelor)

Results

Drop-outs Within 24 h after being randomly assigned, five (2%) patients dropped out of the invasive group as did one (<1%) from the conservative group Invasive group because of discussions the patients had had with their relatives conservative group, the single dropout was because of severe sepsis.

Results (Baseline Characteristics)

Baseline Characteristics baseline characteristics and medical treatment at inclusion and discharge were similar between the groups Except for the use of warfarin and nitrates

Results all randomly assigned patients were analysed as far as the outcome and adverse events, including the dropouts. 457 patients remained in the follow-up study population, with 229 patients (mean age 84·7 years) in the invasive group and 228 patients (mean age 84·9 years) in the conservative group No crossovers between the two strategy groups. Reinfarction, refractory angina pectoris, development of malignant ventricular arrhythmias, or increasing symptoms of heart failure were deemed to require urgent revascularisation—ie, an endpoint

Results

Results The results were consistent when stratifying by sex, type 2 diabetes, creatinine blood concentration of more than 103 μmol/L, use of warfarin, and age older than 90 years. However confounding effect with creatinine and age >90 indicated effect modification

Author’s Conclusion An invasive strategy is superior to conservative strategy in patients with NSTEMI or unstable angina with a reduction in composite events primary endpoint occurred in 93 (41%) patients in the invasive group and in 140 (61%) patients in the conservative group (HR 0·53 [95% CI 0·41–0·69], p=0·0001). Efficacy of invasive strategy was diluted with increasing age (in particular over 90) after adjusting for creatinine and effect modification

Discussion

Strengths of the study RCT Multicentre Power – recruitment Question worth answering – relevant Registered at clinical trials Under-powered for over 90 group which they recognised Good protocol for hiding randomisation – independent

Limitations of the study Open label Aggressive exclusion criteria – 10% of original patients included Patients that didn’t make it into trial eg. Because of ‘logistics’ P values between groups characteristics not listed Quality of life outcome – listed in original trial registration but not yet done

Impact of the study

How has the study impacted on practice In select groups of >80yo an invasive strategy is probably of benefit ?applicability to NZ population No quality of life analysis yet done May be useful to discuss with cardiologists